BRCA2 and ovarian carcinoma: Next, we fit a multivariate linear regression model including uterine disease status (Table 2) which identified eight genomic alterations that associated with increased gLOH, independent of uterine disease status, including homozygous deletion of BRCA2, CDKN2A, CDKN2B, DAXX, NF1, and RB1, as well as amplification of FBXW7, and MYC. In ovarian carcinoma, gLOH has been associated with a number of genes associated with the HR and other DNA repair pathways25.